肿瘤热化疗中化疗药物的选择 - 现代生物医学进展.pdf

Progress in Modern Biomedicine 2006 Vol. 6 No. 4 # 63 # 肿瘤热化疗中化疗药物的选择 彭 楠 马爱敏 ( 100853) : 肿瘤治疗进入综合治疗时代, 临床已应用热疗联合化疗和/ 或放疗治疗多种肿瘤, 但热化疗中还 许多问题需 要明确, 如最佳的温度和作用时间, 热化疗是药物的选择等: 通过总结许多国内外的基础试验研究和临床应用结果, 评价 肿瘤热化疗的协同作用: 体外细胞试验表明化疗药物的毒性与治疗温度和时间相关, 温度37. 0~ 4 1. 0 e (4 1. 5 e ) 合并药 物时, 细胞生存率急剧下降, 而除ADR 外, 41. 0~ 43. 0 e 时细胞生存率下降不明显体内实验表明9 种药物中, 除BLM 外热增长 比例(TER) 在41. 5 e 和43. 0 e 无明显区别, 其中马法兰的TER 最高热化疗的临床研究还处于初期, 但用马法兰和TNF 进行隔 离肢体热灌注治疗黑色素瘤和软组织肉瘤效果确切: 热疗联合化疗 协同抗肿瘤作用, 应进一步深入研究 : 肿瘤治疗; 热化疗; 化疗药物; 细胞生存率 Selection of Chemotherapeutics in Thermochemotherapy of Tumor PENGNan, MA Ai- min Department of Physiotherapy, General Hospital of Liberation Army, Wukesong 100853, Beijing , hina ABSTRACT Objective To dis uss the optimal temperature( OT) and a tion time( AT) , sele tion of hemotherapeuti s in the ther- mo hemotherapy(TCT) of tumor. Methods The synergisti a tion in the TCT of tumor was evaluated by summarizing the basal experimental in- vestigation and lini al appli ation of the internal and external. Results Exosomati ell test showed that the toxi ity of hemotherapeuti s was relative to treating temperature and time. When the temperature was 37. 0- 41. 00C(41. 50C) with medi ation, ell survival rates de reased sud- denly ex ept Adr; the test in vivo showed that out of the 9 drugs, L- Sar olysinum. s( L- PAM) TER( = Thermal Enhan ement Ratio) was the highest at 41. 50C and 43. 00C, ex ept BLM without signifi ant differen e. Although the lini al study on TCT is still in the initial stage, hyper- thermi isolated limb perfusion with L- PAM and TNF in the treatment of melanoma and soft- tissue sar oma has got good effe ts. Conclu- sion Thermotherapy ombined with